SAN FRANCISCO, CA — June 17, 2002 —
New findings in people with type 2 diabetes show that the oral antidiabetic drug (OAD) repaglinide (called Prandin® in the United States, NovoNorm® in Europe (and in Israel as well) , and Gluconorm® in Canada) improves the control of blood glucose more effectively than nateglinide (Starlix®, Novartis) when either OAD is taken alone or in combination with metformin, according to a presentation(1) made here at the annual meeting of the American Diabetes Association.
Although both agents are designed for people with type 2 diabetes to take with meals to control the rise in blood glucose following food consumption, the new findings suggest that the use of repaglinide results in greater improvement in overall blood glucose control (glycemic control).
“Improving glycemic control in diabetes is critical to reducing the risk of long-term complications,(2)(3)” said Mohammed Saad, M.D., the lead author of the presentation and chief of the Division of Clinical Epidemiology and Preventive Medicine at the UCLA School of Medicine Los Angeles, Calif. Complications in type 2 diabetes include coronary heart disease, retinopathy (a common cause of blindness), nephropathy (kidney disease), and microvascular complications and neuropathy (which can lead to limb amputations).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!